Turnstone Biologics

Turnstone Biologics is a New York-based biotechnology company focused on developing innovative therapies to treat and cure patients with solid tumors. Their mission is to address the challenge of low numbers of tumor-reactive T cells by pioneering a differentiated approach to tumor infiltrating lymphocytes (TILs). With a seasoned management team and a distinguished Scientific Advisory Board, Turnstone is dedicated to advancing the field of immunotherapy and improving outcomes for patients with solid tumors.

Turnstone Biologics is committed to developing next-generation TIL therapies, known as Selected TILs, for potential treatment across multiple solid tumors. Led by President and CEO Dr. Sammy Farah, the company brings together world-renowned professionals with deep expertise in TILs, cell therapy, tumor immunology, and biologics development. With a focus on innovation and collaboration, Turnstone is at the forefront of the fight against solid tumors, aiming to deliver on the promise of curative immunotherapies.

Generated from the website